| 2026-08-06 | 10-Q | 10.4 | EX-10.4 REGENERON AMENDMENT 4 |
|---|
| 2026-08-06 | 10-Q | 10.3 | EX-10.3 REGENERON AMENDMENT 3 |
|---|
| 2026-06-22 | 8-K | 10.2 | Amended and Restated CytomX Therapeutics, Inc. Employee Stock Purchase Plan |
|---|
| 2026-06-22 | 8-K | 10.1 | Amended and Restated CytomX Therapeutics, Inc. 2015 Equity Incentive Plan |
|---|
| 2026-03-16 | 10-K | 10.17.B | MODERNA AGREEMENT AMENDMENT |
|---|
| 2026-03-16 | 10-K | 10.8 | OFFER LETTER RACHAEL G LESTER |
|---|
| 2025-11-06 | 10-Q | 10.2 | Office/Laboratory Lease, dated November 3, 2025, by and between CytomX Therapeutics, Inc. and Emery Station West, LLC. |
|---|
| 2025-11-06 | 10-Q | 10.1 | Amendment No. 2 to the Collaboration and License Agreement effective as of October 1, 2025 by and between CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. |
|---|
| 2025-08-07 | 10-Q | 10.2 | Amended and Restated CytomX Therapeutics, Inc. Employee Stock Purchase Plan. |
|---|
| 2025-06-13 | 8-K | 10.2 | Amended and Restated CytomX Therapeutics, Inc. Employee Stock Purchase Plan |
|---|
| 2025-06-13 | 8-K | 10.1 | Amended and Restated CytomX Therapeutics, Inc. 2015 Equity Incentive Plan |
|---|
| 2025-05-12 | 10-Q | 10.1 | SEPARATION AGREEMENT - JL |
|---|
| 2024-08-08 | 10-Q | 10.1 | Amendment No.1 to the Collaboration and License Agreement effective as of June 28, 2024 by and between CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. |
|---|
| 2024-05-08 | 10-Q | 10.1 | Amendment No. 4 to the Collaboration and License Agreement, dated as of March 28, 2024, by and between CytomX Therapeutics, Inc. and Amgen, Inc. |
|---|
| 2023-11-07 | 10-Q | 10.1 | Transition Agreement effective as of August 22, 2023 by and between CytomX Therapeutics, Inc., and AbbVie Global Enterprises Ltd. |
|---|
| 2023-08-08 | 10-Q | 10.3 | Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Jeffrey Landau dated as of March 31, 2021. |
|---|
| 2023-08-08 | 10-Q | 10.2 | Form of Amended and Restated Severance and Change of Control Agreement by and between CytomX Therapeutics, Inc. and each of its executive officers other than Sean A. McCarthy. |
|---|
| 2023-08-08 | 10-Q | 10.1 | Amendment No. 3 to the Collaboration and License Agreement, dated as of May 18, 2023, by and between CytomX Therapeutics, Inc. and Amgen, Inc. |
|---|
| 2023-07-03 | 8-K | 10.1 | Unit Purchase Agreement by and among the Company and the Purchasers, dated June 29, 2023. |
|---|
| 2023-05-09 | 10-Q | 10.1 | Sublease Agreement dated as of March 24, 2023, by and between CytomX Therapeutics, Inc and Atomic AI, Inc. |
|---|
| 2023-03-27 | 10-K | 10.25 | EX-10.25 - MODERNA AGREEMENT |
|---|
| 2023-03-27 | 10-K | 10.24 | EX-10.24 - REGENERON AGREEMENT |
|---|
| 2022-11-08 | 10-Q | 10.6 | Amendment No 3 to Collaboration and License Agreement, dated May 23, 2014, by and between the Company and Bristol Myers Squibb Company, effective as of October 11, 2022. |
|---|
| 2022-11-08 | 10-Q | 10.5 | Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc. and Alison Hannah, M.D. |
|---|
| 2022-11-08 | 10-Q | 10.4 | Separation Agreement effective as of September 12, 2022, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D. |
|---|
| 2022-11-08 | 10-Q | 10.3 | Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc. and Carlos Campoy. |
|---|
| 2022-11-08 | 10-Q | 10.2 | Consulting Agreement effective as of September 13, 2022, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D. |
|---|
| 2022-11-08 | 10-Q | 10.1 | Consulting Agreement effective as of October 1, 2022, by and between CytomX Therapeutics, Inc. and Carlos Campoy. |
|---|
| 2022-03-01 | 10-K | 10.20 | Amendment No. 2 to the Collaboration and License Agreement, dated as of October 27, 2021, by and between CytomX Therapeutics, Inc. and Amgen, Inc. |
|---|
| 2022-03-01 | 10-K | 10.3 | Form of 2015 Plan Restricted Share Unit Award Grant Notice and Agreement |
|---|
| 2021-05-06 | 10-Q | 10.3 | EX-10.3 - FUCHS CONSULTING AGREEMENT |
|---|
| 2021-05-06 | 10-Q | 10.2 | EX-10.2 - BMS AMENDMENT 2 |
|---|
| 2021-02-24 | 10-K | 10.25 | EX-10.25_MK RETIREMENT AGREEMENT |
|---|
| 2021-02-24 | 10-K | 10.24 | EX-10.24 - MK CONSULTING AGREEMENT |
|---|
| 2020-11-05 | 10-Q | 10.3 | EX-10.3 - AMENDMENT NO. 1 WITH AMGEN |
|---|
| 2020-11-05 | 10-Q | 10.2 | EX-10.2 - BMS AGREEMENT |
|---|
| 2020-11-05 | 10-Q | 10.1 | EX-10.1 - PFIZER AGREEMENT |
|---|
| 2020-05-07 | 10-Q | 10.4 | EX-10.4 - ASTELLAS COLLABORATION AGREEMENT |
|---|
| 2020-05-07 | 10-Q | 10.3 | EX-10.3 - CFO OFFER LETTER |
|---|
| 2020-05-07 | 10-Q | 10.1 | EX-10.1 - CIC AGREEMENT - CC |
|---|
| 2020-02-27 | 10-K | 10.32 | EX-10.32 - SEVERANCE AGREEMENT OF HANNAH ALISON |
|---|
| 2019-11-07 | 10-Q | 10.6 | Severance and Change of Control Agreement effective as of October 14, 2019, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D. |
|---|
| 2019-11-07 | 10-Q | 10.5 | Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D. dated as of September 23, 2019. |
|---|
| 2019-11-07 | 10-Q | 10.4 | Separation Agreement effective as of September 5, 2019, by and between CytomX Therapeutics, Inc. and Rachel W. Humphrey, M.D. |
|---|
| 2019-11-07 | 10-Q | 10.3 | Consulting Agreement effective as of August 19, 2019, by and between CytomX Therapeutics, Inc. and Rachel W. Humphrey, M.D. |
|---|
| 2019-11-07 | 10-Q | 10.2 | Form of Stock Option Agreement under the 2019 Plan |
|---|
| 2019-11-07 | 10-Q | 10.1 | 2019 Employment Inducement Incentive Plan adopted on September 18, 2019 (“2019 Plan”) |
|---|
| 2019-08-07 | 10-Q | 10.1 | Amended and Restated Discovery Collaboration and License Agreement, dated as of June 28, 2019, by and between CytomX Therapeutics, Inc., and AbbVie Ireland Unlimited Company. |
|---|
| 2019-05-09 | 10-Q | 10.7 | Consulting Agreement effective as of May 15, 2019, by and between CytomX Therapeutics, Inc. and Debanjan Ray. |
|---|
| 2019-05-09 | 10-Q | 10.6 | Amendment No.3 to Exclusive License Agreement effective as of April 2, 2019, by and between CytomX Therapeutics, Inc. and The Regents of the University of California. |
|---|
| 2019-05-09 | 10-Q | 10.5 | Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Debanjan Ray. |
|---|
| 2019-05-09 | 10-Q | 10.4 | Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Michael Kavanaugh, M.D. |
|---|
| 2019-05-09 | 10-Q | 10.3 | Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Rachel W. Humphrey, M.D. |
|---|
| 2019-05-09 | 10-Q | 10.2 | Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Lloyd Rowland. |
|---|
| 2019-05-09 | 10-Q | 10.1 | Amended and Restated Severance and Change of Control Agreement dated February 27, 2019, by and between CytomX Therapeutics, Inc. and Sean McCarthy. D. Phil. |
|---|
| 2019-02-27 | 10-K | 10.27 | Consulting Agreement between CytomX Therapeutics, Inc and Dr. Hoyoung Huh, effective as of December 30, 2018. |
|---|
| 2018-11-06 | 10-Q | 10.6 | Third Amendment to the Research Collaboration Agreement by and between CytomX Therapeutics, Inc. and ImmunoGen Inc., dated as of March 3, 2017. |
|---|
| 2018-11-06 | 10-Q | 10.5 | Second Amendment to the Research Collaboration Agreement by and between CytomX Therapeutics, Inc. and ImmunoGen Inc., dated as of February 12,2016. |
|---|
| 2018-11-06 | 10-Q | 10.4 | License Agreement by and between CytomX Therapeutics, Inc. and ImmunoGen Inc., dated as of February 12,2016. |
|---|
| 2018-11-06 | 10-Q | 10.3 | Third Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, dated as of January 3, 2018. |
|---|
| 2018-11-06 | 10-Q | 10.2 | Second Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, dated as of March 31, 2017. |
|---|
| 2018-11-06 | 10-Q | 10.1 | First Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, dated as of October 5, 2016. |
|---|
| 2018-08-08 | 10-Q | 10.1 | Severance and Change of Control Agreement, by and between CytomX Therapeutics, Inc. and Lloyd Rowland, dated as of May 16, 2018. |
|---|
| 2017-11-07 | 10-Q | 10.1 | Collaboration and License Agreement by and between CytomX Therapeutics, Inc. and Amgen, Inc. dated as of September 29, 2017 |
|---|
| 2017-08-07 | 10-Q | 10.2 | Severance and Change of Control Agreement, by and between CytomX Therapeutics, Inc. and Debanjan Ray, dated as of May 15, 2017. |
|---|
| 2017-08-07 | 10-Q | 10.1 | Separation Agreement, dated May 15, 2017, by and between the Company and Robert C. Goeltz. |
|---|
| 2017-05-05 | 10-Q | 10.1 | Amendment to Extend Collaboration and License Agreement, dated March 17, 2017, by and between the Company and Bristol-Myers Squibb. |
|---|
| 2017-03-02 | 10-K | 10.8.C | Severance and Change of Control Agreement and First Amendment to Severance and Change of Control Agreement effective as of March 23, 2016, by and between CytomX Therapeutics, Inc. and Cynthia J. Ladd. |
|---|
| 2017-03-02 | 10-K | 10.7.C | Severance and Change of Control Agreement and First Amendment to Severance and Change of Control Agreement effective as of March 23, 2016, by and between CytomX Therapeutics, Inc. and Michael Kavanaugh, M.D. |
|---|
| 2017-03-02 | 10-K | 10.6.C | Severance and Change of Control Agreement and First Amendment to Severance and Change of Control Agreement effective as of March 23, 2016, by and between CytomX Therapeutics, Inc. and Robert C. Goeltz. |
|---|
| 2017-03-02 | 10-K | 10.5.C | Amended and Restated Severance and Change of Control Agreement effective as of October 3, 2016, by and between CytomX Therapeutics, Inc. and Sean McCarthy, D. Phil. |
|---|
| 2016-08-03 | 10-Q | 10.2 | Discovery Collaboration and License Agreement, dated April 21, 2016, by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company. |
|---|
| 2016-08-03 | 10-Q | 10.1 | Co-Development and License Agreement, dated April 21, 2016, by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company. |
|---|
| 2016-05-06 | 10-Q | 10.2 | Severance and Change of Control Agreement |
|---|
| 2016-03-07 | 8-K | 10.1 | Form of First Amendment to Severance and Change of Control Agreement by and between CytomX Therapeutics, Inc. and certain of its officers. |
|---|
| 2015-12-16 | 8-K | 10.1 | Lease dated as of December 10, 2015, by and between CytomX Therapeutics, Inc. and HCP Oyster Point III LLC. |
|---|
| 2015-11-23 | 10-Q | 10.5 | Form of 2015 Equity Incentive Plan Early Exercise Option Agreement. |
|---|
| 2015-11-23 | 10-Q | 10.4 | Form of 2015 Equity Incentive Plan Option Agreement. |
|---|